Susan Sidwell represents businesses in a variety of capital raising endeavors, from WKSIs that frequently access the market to newly formed entities raising their initial capital. For more than 25 years, Susan has advised private companies on preparing to go public and public companies on ongoing SEC compliance, corporate governance issues and compliance with various stock exchanges. In addition, she helps clients with regulatory and fiduciary obligations in the context of strategic transactions such as mergers, going private transactions and tender offers. Susan applies her accounting background to assist clients with the technical side of securities work, guiding clients through complex SEC filings. Throughout her career she has worked with clients in a wide variety of industries, including healthcare, life sciences and biotechnology, real estate, insurance software, technology and others. Her practice includes:
Prior to joining Bass, Berry & Sims, Susan was a shareholder at Harwell Howard Hyne Gabbert & Manner, P.C.
Nashville Bar Association
Tennessee Bar Association
American Bar Association
American Health Law Association (AHLA)
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.
Representation of Heritage Global Inc. (Nasdaq: HGBL), an asset services company specializing in financial and industrial assets, in its public offering of 5,462,500 shares of common stock with proceeds of $9,559,375. The underwriters included Lake Street Capital Markets, LLC and Colliers Securities, LLC.
Representation of LucidHealth, a portfolio company of Excellere Partners, in its acquisition of Madison Radiologists
We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.
Represented NN, Inc. (Nasdaq: NNBR) in its public offering of 14,375,000 shares of common stock
Represented NN, Inc. (Nasdaq: NNBR) in its acquisition of Paragon Medical
Represented infrastructure technology solutions provider in its sell to Data Blue
Represented AmSurg Corp. (NASDAQ: AMSG) in its merger with Envision Healthcare Holdings, Inc. (NYSE: EVHC)
Advised BioMimetic Therapeutics, Inc. in the sale of its orofacial therapeutic business to Luitpold Pharmaceuticals, Inc.
The Best Lawyers in America© — Securities/Capital Markets (2013-2023)